Rasburicase Injection

Form: IV infusion

Strength: 7.5 mg/15 mL vial

Reference Brands: Elitek(US)

Category: Oncology Cancer Care

Rasburicase Injection 7.5 mg/15 mL is a critical treatment for tumor lysis syndrome (TLS), commonly associated with hematologic cancers like leukemia and lymphoma. By converting uric acid into allantoin, Rasburicase reduces the risk of kidney damage caused by high uric acid levels. Approved in both the U.S. and EU, Elitek (brand name in the U.S.) is supplied as a sterile IV solution for infusion. Rasburicase is essential for B2B pharmaceutical distribution, supporting oncology care centers, hospitals, and clinics with essential treatment for high-risk cancer patients undergoing chemotherapy.